石四药集团(02005):间苯三酚三甲醚及盐酸多巴酚丁胺已获国家药监局批准登记成为在上市制剂使用的原料药

智通财经
Feb 09

智通财经APP讯,石四药集团(02005)发布公告,本集团的间苯三酚三甲醚及盐酸多巴酚丁胺已获中国国家药品监督管理局(国家药监局)批准登记成为在上市制剂使用的原料药。

间苯三酚三甲醚主要用于制备间苯三酚注射液,其主要用于治疗消化系统和胆道功能障碍引起的急性痉挛疼痛;急性痉挛性尿道、膀胱、肾绞痛;及妇科痉挛性疼痛。诚如本公司日期为2024年8月27日的公告所载,本集团已取得国家药监局有关间苯三酚注射液的药品生产注册批件。

盐酸多巴酚丁胺主要用于制备盐酸多巴酚丁胺注射液,其主要用于器质性心脏病时心肌收缩力下降引起的心力衰竭,包括心脏直视手术后所致的低排血量综合症。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10